Kanuma Market Report 2026

Kanuma Market Overview

• The Kanuma market growth in the historic period has been driven by lack of effective lal-d treatments, historical liver disease complications • Market expansion is supported by expansion of newborn screening programs, advancements in recombinant enzyme technology • Growth Driver: Rising Prevalence Of Lysosomal Acid Lipase Deficiency To Drive Kanuma Market Growth • Market Trend: Enzyme Replacement Therapy (ERT) Drives Growth In The Kanuma Market, With NHS Approval For Wolman Disease • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Kanuma Market?

Kanuma (sebelipase alfa) is a recombinant enzyme replacement therapy used to treat lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder. LAL-D leads to the accumulation of lipids in tissues, causing liver damage, cardiovascular issues, and other complications. Kanuma works by replacing the deficient LAL enzyme, enabling the breakdown of lipid deposits in the body. The main indication types of kanuma are the treatment of lysosomal acid lipase deficiency and treatment of associated conditions. Treatment of lysosomal acid lipase deficiency (LAL-D) primarily involves enzyme replacement therapy (ERT), such as kanuma, to replace the deficient lysosomal acid lipase enzyme. The formulations are injectable formulations and lyophilized powders for reconstitution, and the patient demographics include pediatric patients, adult patients, and geriatric patients. The distribution channels are direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and it is used by various end users such as hospitals, specialty clinics, home healthcare providers, and research institutions.

What Is The Kanuma Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of newborn screening programs, advancements in recombinant enzyme technology, rising rare disease awareness, improved access to specialty care, increased healthcare funding for orphan therapies. Major trends in the forecast period include expansion of enzyme replacement therapies, rising focus on lipid metabolism disorders, growth in pediatric rare disease treatment, improved long term disease management, increasing early diagnosis of lal-d.

Global Kanuma Market Segmentation

1) By Indication: Treatment Of Lysosomal Acid Lipase Deficiency, Treatment Of Associated Conditions 2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution 3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients 4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies 5) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers, Research Institutions

What Are The Drivers Of The Kanuma Market?

The increasing prevalence of lysosomal acid lipase deficiency (LAL-D) is expected to drive the kanuma market going forward. LAL-D is a rare genetic disorder that leads to the accumulation of lipids in organs, resulting in liver dysfunction, cardiovascular issues, and metabolic disturbances. The increasing prevalence of lysosomal acid lipase deficiency (LAL-D) is attributed to improved diagnostic techniques and heightened awareness, leading to better detection of this rare genetic disorder. Kanuma is used to treat lysosomal acid lipase deficiency (LAL-D) by replacing the deficient enzyme, helping to reduce lipid accumulation and prevent organ damage. For instance, in March 2023, according to a report published by the National Institutes of Health, a US-based health research agency, estimates suggest the overall disease prevalence of lysosomal acid lipase deficiency (LAL-D) ranges from 1:40,000 to 1:300,000, depending on ethnicity and geographical location. Therefore, the increasing prevalence of lysosomal acid lipase deficiency (LAL-D) drives the kanuma industry. The rise in healthcare expenditure is expected to fuel the kanuma market going forward. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal health care, preventive services, and public health activities, aimed at improving health outcomes within a specific period. Healthcare expenditure is rising due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Healthcare expenditure for Kanuma involves costs related to enzyme replacement therapy, including the price of the drug, administration, and ongoing patient monitoring. For instance, in May 2024, according to a report published by Office For National Statistics, a UK-based government agency, total healthcare spending rose by 5.6% in nominal terms from 2022 to 2023, a notable acceleration compared with the 0.9% increase recorded in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the rise in healthcare expenditure drives the Kanuma industry.

Key Players In The Global Kanuma Market

Major companies operating in the kanuma market are AstraZeneca PLC

Global Kanuma Market Trends and Insights

A key trend in the kanuma market is focusing on enzyme replacement therapy (ERT) to gain a competitive edge in the industry. ERT, including Kanuma, replaces the deficient lysosomal acid lipase enzyme, reducing lipid accumulation in organs and mitigating severe complications associated with LAL-D. For instance, in November 2023, according to a report published by the National Health Service (NHS), the UK-based publicly funded healthcare system announced that sebelipase alfa (Kanuma), an ERT, will be the first treatment available on the NHS for Wolman disease, a rare and fatal genetic condition affecting babies and toddlers. This development follows a commercial deal by NHS England and a recommendation by the National Institute for Health and Care Excellence (NICE).

Regional Insights

North America was the largest region in the kanuma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Kanuma Market?

The kanuma market consists of sales of single-dose vials, intravenous infusion solutions, and ready-to-use formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Kanuma Market Report 2026?

The kanuma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the kanuma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.